ReviewFrontiers in immunology2026
Clinical value of IL-17-targeted intervention in tissue injury repair: from bidirectional mechanisms to therapeutic strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-17, a pleiotropic cytokine, activates downstream signaling pathways through the IL-17 receptor (IL-17R), influencing the expression and regulation of inflammatory mediators, growth factors, and matrix metalloproteinases, thereby modulating various biological processes. Recent studies have shown that IL-17 exhibits dynamic biphasic effects during tissue repair: in the acute phase, it accelerates tissue repair by promoting epithelial regeneration, angiogenesis, and the recruitment of reparative immune cells, whereas in the chronic phase, excessive activation leads to uncontrolled inflammation and fibrosis progression. This "double-edged sword" effect shows significant heterogeneity across different tissues, including the skin, lungs, and intestines. Despite the widely recognized dual roles of IL-17, the field still lacks a holistic perspective that systematically explains how this duality is regulated across different tissue environments. This review outlines recent advances in IL-17's functional dichotomy and identifies cellular origin, injury phase, and local microenvironment as critical regulatory determinants. We aim to elucidate under what circumstances and why IL-17 promotes tissue repair rather than exacerbates fibrosis, and discuss the implications of these insights for developing therapeutic strategies tailored to distinct clinical scenarios.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.